他汀类药物是最常用的降低胆固醇的药物，既有改善乳腺癌预后的报道，也有无变化的报道。本研究探讨了奈及利亚女性化疗后使用他汀类药物与乳腺癌预后（死亡和复发）的关系。该研究选取了一组新西兰地区符合标准且代表性较强的乳腺癌女性样本，通过与国家药品数据、住院记录以及死亡记录相连结的方式，考察了使用他汀类药物与特异性死亡的风险。共有14,976名女性参与研究，其中27%女性在诊断后使用了他汀类药物，随访中位数为4.51年。研究结果显示，相对于未使用，使用他汀类药物可明显降低乳腺癌特异性死亡的风险（调整风险比：0.74; 0.63-0.86）。当考虑“新”他汀类药物使用的亚组时，相关性会有所减弱（风险比：0.91; 0.69-1.19）。然而，其他分析结果表明，在雌激素受体阳性患者、绝经后妇女和晚期患者中，他汀类药物的保护作用更加显著（风险比：0.77; 0.63-0.94, 风险比：0.74; 0.63-0.88, 风险比：0.65; 0.49-0.84）。本研究表明，使用他汀药物可显著降低乳腺癌死亡风险，亚组分析表明，在雌激素受体阳性患者、绝经后妇女和晚期患者中，其保护作用更加显著。进一步的研究还需在其他临床环境中进行。 © 2023. 作者 (S)。

Statins are the most widely prescribed cholesterol lowering medications and have been associated with both improved and unchanged breast cancer outcomes in previous studies. This study examines the association between the post-diagnostic use of statins and breast cancer outcomes (death and recurrence) in a large, representative sample of New Zealand (NZ) women with breast cancer.Women diagnosed with a first primary breast cancer between 2007 and 2016 were identified from four population-based regional NZ breast cancer registries and linked to national pharmaceutical data, hospital discharges, and death records. Cox proportional hazard models were used to estimate the hazard of breast cancer-specific death (BCD) associated with any post-diagnostic statin use.Of the 14,976 women included in analyses, 27% used a statin after diagnosis and the median follow up time was 4.51 years. Statin use (vs non-use) was associated with a statistically significant decreased risk of BCD (adjusted hazard ratio: 0.74; 0.63-0.86). The association was attenuated when considering a subgroup of 'new' statin users (HR: 0.91; 0.69-1.19), however other analyses revealed that the protective effect of statins was more pronounced in estrogen receptor positive patients (HR: 0.77; 0.63-0.94), postmenopausal women (HR: 0.74; 0.63-0.88), and in women with advanced stage disease (HR: 0.65; 0.49-0.84).In this study, statin use was associated with a statistically significant decreased risk of breast cancer death, with subgroup analyses revealing a more protective effect in ER+ patients, postmenopausal women, and in women with advanced stage disease. Further research is warranted to determine if these associations are replicated in other clinical settings.© 2023. Author(s).